Nanohybrid drug delivery vehicle could help treat Alzheimer’s
The chitosan drug delivery vehicle could be used for administering polyphenol ellagic acid (EA), a potential antioxidant treatment for Alzheimer’s and Parkinson’s.
List view / Grid view
The chitosan drug delivery vehicle could be used for administering polyphenol ellagic acid (EA), a potential antioxidant treatment for Alzheimer’s and Parkinson’s.
Modified ‘super-human’ red blood cells containing therapeutic compounds have been developed by researchers as a novel form of drug delivery.
A business selling unapproved products containing CBD has been sent a warning letter from the FDA and FTC for making unsubstantiated claims about their therapeutic properties.
As part of EPR’s Women Inspiring Pharma series, Shehnaaz Suliman, SVP, Business Development and Strategy, Theravance Biopharma talks to Science Editor Dr Zara Kassam about fighting for human rights, inequality and the challenges women face in their careers...
A study shows low-dose aspirin may aid removal of harmful amyloid plaque in the brain...
A landmark £40million has been awarded to the UK Dementia Research Institute, via the Medical Research Council, for a new iconic hub building at University College London...
PET imaging may improve diagnosis and monitoring for MS patients...
US science minister announce new multi-million-pound commitment to boost the burgeoning field of cryo-electron microscopy (cryo-EM) in the UK.
Twenty-seven Alzheimer's drugs in Phase III clinical trials and eight drugs in Phase II clinical trials may launch in the next five years...
By 2040, there will be over 1.2 million people living with dementia in England and Wales (an increase of 57% from 2016), due to increased life expectancy...
23 August 2016 | By AstraZeneca
AstraZeneca and Eli Lilly and Company have received US FDA Fast Track designation for the development programme in Alzheimer’s disease for AZD3293, an oral beta secretase cleaving enzyme inhibitor currently in Phase III clinical trial.
20 July 2016 | By Victoria White, Digital Content Producer
The US Food and Drug Administration (FDA) has approved an expanded label for Namzaric.
11 July 2016 | By Victoria White, Digital Content Producer
If approved, RVT-101 could be the first Alzheimer’s treatment in 14 years. The last drug to be approved to help improve cognition was Donepezil in 2002...
2 June 2016 | By Victoria White, Digital Content Producer
PRIME aims to bring treatments to patients faster by enhancing the EMA’s support for the development of investigational medicines...
8 April 2016 | By Victoria White
AstraZeneca and Lilly have announced that AMARANTH, a Phase II/III study of AZD3293 will continue into Phase III of the Phase II/III seamless trial...